9 research outputs found
Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing.
BACKGROUND: Whole-exome sequencing (WES) has been successful in identifying genes that cause familial Parkinson's disease (PD). However, until now this approach has not been deployed to study large cohorts of unrelated participants. To discover rare PD susceptibility variants, we performed WES in 1148 unrelated cases and 503 control participants. Candidate genes were subsequently validated for functions relevant to PD based on parallel RNA-interference (RNAi) screens in human cell culture and Drosophila and C. elegans models. RESULTS: Assuming autosomal recessive inheritance, we identify 27 genes that have homozygous or compound heterozygous loss-of-function variants in PD cases. Definitive replication and confirmation of these findings were hindered by potential heterogeneity and by the rarity of the implicated alleles. We therefore looked for potential genetic interactions with established PD mechanisms. Following RNAi-mediated knockdown, 15 of the genes modulated mitochondrial dynamics in human neuronal cultures and four candidates enhanced α-synuclein-induced neurodegeneration in Drosophila. Based on complementary analyses in independent human datasets, five functionally validated genes-GPATCH2L, UHRF1BP1L, PTPRH, ARSB, and VPS13C-also showed evidence consistent with genetic replication. CONCLUSIONS: By integrating human genetic and functional evidence, we identify several PD susceptibility gene candidates for further investigation. Our approach highlights a powerful experimental strategy with broad applicability for future studies of disorders with complex genetic etiologies
The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients.
The most common cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) is a G4C2-repeat expansion in C9orf72. However, the lower limit for pathological repeats has not been established and expansions with different sizes could have different pathological consequences. One of the implicated disease mechanisms is haploinsufficiency. Previously, we identified expansion-specific hypermethylation at the 5´ CpG-island near the G4C2-repeat, but only in a fraction of carriers (up to 36 %). Here, we tested the hypothesis that the G4C2-repeat itself could be the main site of methylation. To evaluate (G4C2) n -methylation, we developed a novel assay, which was validated by an independent methylation-sensitive restriction enzyme assay. Notably, both assays are qualitative but not quantitative. Blood DNA was available for 270 unrelated individuals, including 71 expansion carriers. In addition, we investigated blood DNA from family members of 16 probands, and 38 DNA samples from multiple tissues of 10 expansion carriers. Finally, we tested DNA from different tissues of an ALS patient carrying a somatically unstable 90-repeat. We demonstrated that the G4C2-expansion is generally methylated in unrelated carriers of alleles >50 repeats (97 %), while small (<22 repeats) or intermediate (22-90 repeats) alleles were completely unmethylated. The presence of (G4C2) n -methylation does not separate the C9orf72-phenotypes (ALS vs. ALS/FTLD vs. FTLD), but has the potential to predict large vs. intermediate repeat length. Our results suggest that (G4C2) n -methylation might sometimes spread to the 5´-upstream region, but not vice versa. It is stable over time, since (G4C2) n -methylation was detected in carriers with a wide range of ages (24-74 years). It was identified in both blood and brain tissues for the same individual, implying its potential use as a biomarker. Furthermore, our findings may open up new perspectives for studying disease mechanisms, such as determining whether methylated and unmethylated repeats have the same ability to form a G-quadruplex configuration.Fil: Xi, Zhengrui. University of Toronto; CanadáFil: Zhang, Ming. University of Toronto; CanadáFil: Bruni, Amalia C.. No especifĂca;Fil: Maletta, Raffaele G.. No especifĂca;Fil: Colao, Rosanna. No especifĂca;Fil: Fratta, Pietro. UCL Queen Square Institute of Neurology; Reino UnidoFil: Polke, James M.. National Hospital for Neurology and Neurosurgery; Reino UnidoFil: Sweeny, Mary G.. National Hospital for Neurology and Neurosurgery; Reino UnidoFil: Mudanohwo, Ese. National Hospital for Neurology and Neurosurgery; Reino UnidoFil: Nacmias, Benedetta. Universidad de Florencia
; ItaliaFil: Sorbi, Sandro. Universidad de Florencia; ItaliaFil: Tartaglia, Maria Carmela. University of Toronto; CanadáFil: Rainero, Innocenzo. UniversitĂ di Torino; ItaliaFil: Rubino, Elisa. UniversitĂ di Torino; ItaliaFil: Pinessi, Lorenzo. UniversitĂ di Torino; ItaliaFil: Galimberti, Daniela. University of Milan; ItaliaFil: Surace, Ezequiel Ignacio. FundaciĂłn para la Lucha Contra las Enfermedades NeurolĂłgicas de la Infancia. Instituto de Investigaciones NeurolĂłgicas "RaĂşl Carrea"; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: McGoldrick, Philip. University of Toronto; CanadáFil: McKeever, Paul. University of Toronto; CanadáFil: Moreno, Danielle. University of Toronto; CanadáFil: Sato, Christine. University of Toronto; CanadáFil: Liang, Yan. University of Toronto; CanadáFil: Keith, Julia. No especifĂca;Fil: Zinman, Lorne. No especifĂca;Fil: Robertson, Janice. University of Toronto; CanadáFil: Rogaeva, Ekaterina. University of Toronto; Canad
Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia
Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease
Mutations in the glucocerebrosidase gene (GBA), which cause Gaucher disease, are also potent risk factors for Parkinson's disease. We examined whether a genetic burden of variants in other lysosomal storage disorder genes is more broadly associated with Parkinson's disease susceptibility. The sequence kernel association test was used to interrogate variant burden among 54 lysosomal storage disorder genes, leveraging whole exome sequencing data from 1156 Parkinson's disease cases and 1679 control subjects. We discovered a significant burden of rare, likely damaging lysosomal storage disorder gene variants in association with Parkinson's disease risk. The association signal was robust to the exclusion of GBA, and consistent results were obtained in two independent replication cohorts, including 436 cases and 169 controls with whole exome sequencing and an additional 6713 cases and 5964 controls with exome-wide genotyping. In secondary analyses designed to highlight the specific genes driving the aggregate signal, we confirmed associations at the GBA and SMPD1 loci and newly implicate CTSD, SLC17A5, and ASAH1 as candidate Parkinson's disease susceptibility genes. In our discovery cohort, the majority of Parkinson's disease cases (56%) have at least one putative damaging variant in a lysosomal storage disorder gene, and 21% carry multiple alleles. Our results highlight several promising new susceptibility loci and reinforce the importance of lysosomal mechanisms in Parkinson's disease pathogenesis. We suggest that multiple genetic hits may act in combination to degrade lysosomal function, enhancing Parkinson's disease susceptibility
A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease
A previous genome-wide association (GWA) meta-analysis of 12,386 PD cases and 21,026 controls conducted by the International Parkinson's Disease Genomics Consortium (IPDGC) discovered or confirmed 11 Parkinson's disease (PD) loci. This first analysis of the two-stage IPDGC study focused on the set of loci that passed genome-wide significance in the first stage GWA scan. However, the second stage genotyping array, the ImmunoChip, included a larger set of 1,920 SNPs selected on the basis of the GWA analysis. Here, we analyzed this set of 1,920 SNPs, and we identified five additional PD risk loci (combined p <5x10(-10), PARK16/1q32, STX1B/16p11, FGF20/8p22, STBD1/4q21, and GPNMB/7p15). Two of these five loci have been suggested by previous association studies (PARK16/1q32, FGF20/8p22), and this study provides further support for these findings. Using a dataset of post-mortem brain samples assayed for gene expression (n = 399) and methylation (n = 292), we identified methylation and expression changes associated with PD risk variants in PARK16/1q32, GPNMB/7p15, and STX1B/16p11 loci, hence suggesting potential molecular mechanisms and candidate genes at these risk loc